Particle News: Latest Lecanemab news

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. In clinical trials, it demonstrated modest efficacy in reducing relative cognitive decline compared to placebo.

Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

Biogen Boosts Profit Forecast as Alzheimer's Drug Leqembi Gains Traction

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety

Biogen Raises 2024 Profit Forecast Following Strong Q2 Earnings

EU Regulator Denies Approval for Alzheimer's Drug Lecanemab

FDA Reviewers Weigh Safety and Approval Scope for Eli Lilly’s Alzheimer’s Drug

Biogen's Alzheimer's Drug Leqembi Exceeds Sales Expectations

Biogen Discontinues Controversial Alzheimer's Drug Aduhelm

Drugmakers Report New Alzheimer's Treatments Show Promising Results in Early Diagnosis and Convenience of Administration

Biogen to cut 1,000 jobs as it prepares for Alzheimer's drug launch

FDA Approves Leqembi, First Drug To Slow Progression of Alzheimer's Disease

FDA Panel Unanimously Recommends Approval of Alzheimer’s Drug Leqembi

FDA Approves First Drug Proven to Slow Progression of Alzheimer's Disease